The Nexus of COPD, Cardiovascular Disease, and COVID-19: Key Strategies To Optimize Outcomes
Chronic obstructive pulmonary disease (COPD) is a chronic, complex disease with multiple systemic effects, including cardiometabolic conditions, which not only influence patient adherence by adding to the burden of pharmacotherapy, but may also impact COPD therapeutic decisions.
The updated GOLD 2021 COPD guidelines point out several advances for the assessment and treatment of COPD, including the management of COPD patients with comorbidities, and the impact of the ongoing COVID-19 pandemic in COPD management. This interactive infographic activity will walk you through these updated guidelines by using high-impact visuals to summarize the evidence, as well as offer expert perspectives to optimize the management of COPD patients with existing cardiometabolic disease.
US-based healthcare professionals, including pulmonologists, cardiologists, primary care physicians, nurse practitioners, nurses, physician assistants, and pharmacists.
- List the cardiometabolic comorbidities commonly associated with COPD and their impact on COPD management and outcomes
- Apply GOLD 2021 guidelines for the assessment and management of COPD patients with comorbid CVD, based on the latest evidence, efficacy and safety of pharmacotherapies, and patient preferences
- Identify multi-faceted approaches, including effective clinician-patient communication and collaborative multidisciplinary team care, in order to improve the continuity of care and overall outcomes in COPD patients with cardiovascular comorbidities
- Discuss the impact of COVID-19 in patients with COPD and its implications for COPD management
- Review the preventive measures that should be adapted by health professionals while treating COPD patients in the COVID-19 era
Jill Ohar, MD
Professor of Medicine
Wake Forest University School of Medicine
Dr. Ohar discloses the following:
Consulting Fees: BI, GSK, TEVA, AZ Wallace and Graham, Beasely Allan, Hughes Hubbard Garrisin Law Kazan McClein Satterly,& Greenwood
Contracted Research: Sunovion and BI
Don D. Sin, MD, MPH
Professor of Medicine
University of British Columbia (UBC)
Dr. Sin has nothing to disclose.
Jointly provided by Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC).
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Tarsus Cardio Inc. dba Cardiometabolic Health Congress (CMHC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AMA PRA Category 1 CreditTM
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credits commensurate with the extent of their participation in the activity.
CNE Contact Hours
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.00 contact hours. Pharmacotherapy contact hours for Advanced Practice Registered Nurses will be designated on your certificate.
CE for Pharmacists
Postgraduate Institute for Medicine designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number (UAN): JA4008162-9999-21-2624-H01-P
Type of Activity: Knowledge
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
- 1.00 AMA PRA Category 1 Credit™
This course is offered through MyCME.
To take this course you will be redirected to MyCME's website. You must login or create an account with MyCME in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!